2/3/2023

On February 2, ZM pharmaceutical announced an exclusive worldwide license agreement with GSK for its proprietary TLR8 agonist CB06. Under the agreement, GSK will be allowed to develop, manufacture and commercialize CB06 upon successful completion of a Phase 1 clinical study, which, if successful, could potentially provide a functional cure for more patients with hepatitis B, either as a combination or in sequential therapy with bepirovirsen. Bepirovirsen is an antisense oligonucleotide therapy jointly developed by GSK and Lonis Pharmaceutical.